Lyell Immunopharma, Inc. Quarterly Marketable Securities, Current in USD from Q4 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of investment in marketable security, classified as current.
Summary
Lyell Immunopharma, Inc. quarterly Marketable Securities, Current history and growth rate from Q4 2020 to Q2 2024.
  • Lyell Immunopharma, Inc. Marketable Securities, Current for the quarter ending June 30, 2024 was $358M, a 3.68% decline year-over-year.
Marketable Securities, Current, Quarterly (USD)
Marketable Securities, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $358M -$13.7M -3.68% Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $401M -$103M -20.4% Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $401M -$116M -22.5% Dec 31, 2023 10-Q 2024-08-07
Q3 2023 $289M -$243M -45.6% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $371M -$78.4M -17.4% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $503M +$112M +28.6% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $517M +$196M +61% Dec 31, 2022 10-K 2024-02-28
Q3 2022 $532M +$306M +136% Sep 30, 2022 10-Q 2022-11-08
Q2 2022 $450M +$190M +73% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $391M Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $321M -$151M -32% Dec 31, 2021 10-K 2023-02-28
Q3 2021 $225M Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $260M Jun 30, 2021 10-Q 2021-08-12
Q4 2020 $472M Dec 31, 2020 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.